Asthma affects millions globally — but what if a simple breath test could transform how it’s managed? That’s exactly what Bedfont® Scientific Limited aims to achieve with its latest move in India. The company, a global leader in breath analysis for nearly half a century, has joined forces with Rbeck Healthtech Private to make Fractional exhaled Nitric Oxide (FeNO) testing more accessible across the country. And here’s the interesting part — this collaboration not only strengthens India’s respiratory healthcare capacity but could also redefine asthma management for countless patients.
Bedfont® Scientific Limited, based in the UK, has been pioneering non-invasive breath analysis technologies for over 48 years, delivering tools that support clinicians in early diagnosis and effective disease monitoring. By teaming up with Rbeck Healthtech Private — a versatile distributor specializing in pulmonology, cardiology, and rehabilitation — Bedfont is expanding its footprint in India’s growing medical technology sector. Through this partnership, Rbeck now includes the NObreath® device in its portfolio, paving the way for wider access to advanced FeNO testing solutions.
Asthma, a chronic and often misunderstood respiratory condition, has no known cure. Yet, with accurate diagnosis and personalized treatment, individuals can lead active, healthy lives. Here’s where the numbers get serious: India accounts for nearly 13.1% of the world’s asthma burden. That makes access to diagnostic devices like NObreath® not just beneficial, but absolutely necessary. The NObreath® device detects FeNO — a biomarker that reveals Type 2 airway inflammation, a major factor in asthma. In simple terms, this means doctors can understand inflammation levels in the lungs more precisely and tailor treatments more effectively.
As Jason Smith, CEO of Bedfont® Scientific Limited, explained, securing registration for the NObreath® device in India marks an important step toward the company’s mission of global respiratory health equity. “India carries a heavy asthma burden,” he emphasized, “and our goal is to support clinicians with powerful, portable tools that offer deeper insight into airway inflammation.” That insight translates into smarter, more personalized asthma management — with potentially life-saving results.
This development also touches on an alarming reality highlighted by the Global Asthma Report 2022: a sizeable number of Indian asthma sufferers remain undiagnosed or inadequately treated. With this partnership, there’s renewed hope that accessibility to FeNO testing will expand significantly, helping patients receive more accurate diagnoses and, ultimately, better care outcomes.
But here’s where it gets even more intriguing: Could this movement toward non-invasive diagnostic technology signal a broader shift in how India approaches preventive healthcare? As new innovations like NObreath® make precision testing widely available, traditional methods might soon take a back seat — and not everyone agrees on how fast that shift should happen.
So, what do you think — is this partnership the turning point that could reshape asthma care in India, or are there still major challenges that stand in the way of true accessibility? Share your thoughts and let’s discuss how technology, policy, and accessibility intersect in the future of respiratory health.
